Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
NCT06966388Phase 1Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azelaic acid 15% gel vehicle in radiation dermatitis, sponsored by Virginia Commonwealth University. Primary endpoint: Feasibility of twice daily use of topical azelaic acid at 9 weeks. Started Aug 2025; status: recruiting.
02
Drugs
azelaic acid 15% gel vehicle
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT06966388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966388.